Evidence map›Paper›PMID 42454670›Full record

ArticleVeterinary and comparative oncology2026

Enhancing EGFR Inhibition: Monensin and Erlotinib Synergize to Eliminate Cancer Stem Cells in Canine Mammary Tumours.

Tian Fang, Mengxing Zhang, Chang Ma, Min Dong, Xinhao Song, Junqi Wang, Runan Zuo, Jinwei You, Yingfeng Zhao, Shanxiang Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tian FangDepartment of Laboratory Animal, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Mengxing ZhangEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.
Chang MaDepartment of Laboratory Animal, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Min DongDepartment of Laboratory Animal, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Xinhao SongEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.
Junqi WangEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.
Runan ZuoEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.ORCID https://orcid.org/0000-0002-8000-8760
Jinwei YouDepartment of Laboratory Animal, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yingfeng ZhaoThe Third Outpatient Department, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Shanxiang JiangEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.
Dawei GuoEngineering Center of Innovative Veterinary Drugs, Center for Veterinary Drug Research and Evaluation, Nanjing Agricultural University, Nanjing, China.

Funding

Fundamental Research Funds for the Central Universities KYCXJC2025003
6 · The paper itself

Abstract

Canine mammary tumours (CMTs) and human breast cancer (HBC) share highly similar pathological characteristics. Cancer stem cells (CSCs) are critical to breast cancer invasion, metastasis, drug resistance, and recurrence. The experiment utilised CMT cell line CMT-U27 and HBC cell line MDA-MB-231. Cancer stem cell spheres were isolated from the two cell lines by serum-free culture respectively, named as CMT-U27 microspheres (CMT-U27S) and MDA-MB-231 microspheres (MDA-MB-231S), and the proportion of CSCs with the CD44

Indexed as

Antineoplastic AgentsDog DiseasesErbB ReceptorsErlotinib HydrochlorideMammary Neoplasms, AnimalMonensinNeoplastic Stem CellsAnimalsCell Line, TumorDogsDrug SynergismFemaleMiceMice, NudeAntineoplastic AgentsErbB ReceptorsErlotinib HydrochlorideMonensincancer stem cellscanine mammary tumoursEGFR/PI3Kerlotinibmonensin

Identifiers

PMID42454670
PMCPMC13456595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.